Clearmind Medicine Inc. (CMND)
| Market Cap | 2.61M -50.1% |
| Revenue (ttm) | n/a |
| Net Income | -7.90M |
| EPS | -71.49 |
| Shares Out | 1.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,791 |
| Open | 1.820 |
| Previous Close | 1.810 |
| Day's Range | 1.730 - 1.840 |
| 52-Week Range | 1.430 - 524.000 |
| Beta | -1.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 10, 2026 |
About CMND
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; a... [Read more]
Financial Performance
Financial StatementsNews
Psychedelic: SciSparc, Clearmind publish patent application for PTSD treatment
“Psychedelic” is The Fly’s recurring series focused on psychedelic stock news. SCISPARC/CLEARMIND: SciSparc (SPRC) announced earlier this week that its subsidiary, NeuroThera Labs, and Clearmind Medic...
SciSparc, Clearmind publish U.S. patent application for MDMA-PEA combination
SciSparc (SPRC) announced that its subsidiary, NeuroThera Labs, and Clearmind Medicine (CMND) have published a U.S. patent application covering a novel combination of MDMA and N-acylethanolamines, suc...
NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration, and provides guidance addressing clinical ...
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
U.S. publication of the patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration with Neurothera Labs Inc. as the FDA int...
Clearmind Medicine advances CMND-100 to Alcohol Use Disorder patients
Clearmind Medicine (CMND) announced that its independent DSMB has unanimously approved advancing the company’s ongoing FDA-regulated Phase I/II clinical trial to parts B and C of the clinical trial, e...
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND ‑ 100 in patients with Alcohol Use Disorder (AUD) - a key milest...
Clearmind Medicine reports MEAI development program permeation study results
Clearmind Medicine (CMND) announced permeation study results from its ongoing intranasal MEAI development program. The new findings confirm that the enhanced nasal residence time previously demonstrat...
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery
Vancouver, Canada, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and dev...
Clearmind Medicine reports DSMB approves advancing Phase I/II AUD study
Clearmind Medicine (CMND) announced that its independent DSMB has unanimously approved advancing the Company’s ongoing FDA-regulated Phase I/II clinical trial to parts B and C of the clinical trial, e...
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND‑100 in patients with Alcohol Use Disorder (AUD) - a key mileston...
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems Company
Vancouver, Canada, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of...
Clearmind Medicine announces safety results from Part A of CMND-100 tral
Clearmind Medicine (CMND) announced safety results from Part A of its ongoing FDA-regulated Phase I/II clinical trial evaluating CMND-100, the company’s proprietary MEAI-based oral drug candidate, for...
Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial
Vancouver, Canada, July 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Al...
Clearmind Medicine completes Part A of CMND-100 trial
Clearmind Medicine (CMND) announced the completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of AUD. All 24…
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial
Vancouver, Canada, July 28, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (“Clearmind” or “Company”) (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastog...
Clearmind files psychedelic patent application with Hong Kong Patent Office
Clearmind Medicine (CMND) announced the filing of a patent application with the Hong Kong Patent Office for psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder and other me...
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
Vancouver, Canada, July 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (“ Clearmind ”) (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogen - deri...
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
Vancouver, Canada, July 17, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Al...
Clearmind reports positive retention results for intranasal formulation of MEAI
Clearmind Medicine (CMND) announced “compelling” ex vivo mucoadhesion results for its intranasal formulation of MEAI. “Leveraging a nasal drug-delivery system, the new formulation demonstrated markedl...
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering non‑hallucinogenic neuroplastogen‑derived treatments for ...
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
Principal Investigators of the Ongoing Phase I/II a Trial Highlighted Positive Early Experience with Clearmind Medicine's Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder
Clearmind Medicine submits response to HHS request for information
Clearmind Medicine (CMND) announced that it has submitted a formal response to the U.S. Department of Health and Human Services, or HHS, request for information about MEAI’s potential as an…
Clearmind Medicine Responds to the U.S. Administration's RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative
Vancouver, Canada, July 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage a biotech company developing novel, non-hallucinogenic, next-generation, neuroplastogen-de...
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
Vancouver, Canada, July 07, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage a clinical-stage biotech company focused on the discovery and development of novel, non-ha...
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
Vancouver, Canada, June 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of...